Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
AssigneeIntimax Corporation
InventorsAlan D. Cardin, Cornelius L. Van Gorp
Life of this patent
Estimating the term…
Loading patent…
AssigneeIntimax Corporation
InventorsAlan D. Cardin, Cornelius L. Van Gorp
Estimating the term…
Combined use of a heparin cofactor II agonist and a platelet GPIIb/IIIa receptor antagonist to inhibit both platelet aggregation and thrombin generation resulting from disease, injury or responses to wound repairs. The combined use of the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist can achieve these therapeutic benefits while at the same time minimizing or reducing the risk of hemorrhagic side effects (e.g., prolonged bleeding), and without causing undesired antigenic responses. Moreover, certain subtherapeutic amounts of the heparin cofactor II agonist with certain subtherapeutic amounts of a platelet GPIIb/IIIa receptor antagonist can, in combination, be therapeutically effective in inhibiting both platelet aggregation and thrombin generation.
A pharmaceutical combination, which comprises:
The combination of wherein the dermatan sulfate has a molecular weight of from about 2,500 to about 37,500 Daltons.
A method for inhibiting platelet aggregation and thrombin generation, which comprises the step of administering to a mammal in need thereof a combined therapeutically effective amount of a heparin cofactor II agonist and a platelet GPIIb/IIIa receptor antagonist.
Dependencies are inferred from the claim text.